The worldwide impact of the seven-valent pneumococcal conjugate vaccine.
about
Pneumococcal serotype evolution in Western EuropeDissecting the indirect effects caused by vaccines into the basic elementsAdult vaccinationClinical vaccine developmentGenetic Stabilization of the Drug-Resistant PMEN1 Pneumococcus Lineage by Its Distinctive DpnIII Restriction-Modification SystemThe health and economic impact of vaccination with 7-valent pneumococcal vaccine (PCV7) during an annual influenza epidemic and influenza pandemic in ChinaUsing Pneumococcal Carriage Data to Monitor Postvaccination Changes in the Incidence of Pneumococcal Otitis Media.Efficacy of pneumococcal nontypable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in young Latin American children: A double-blind randomized controlled trial.Impact of pneumococcal conjugate vaccines on the incidence of pneumonia in hospitalized children after five years of its introduction in Uruguay.Potential opportunities and perils of imperfect dengue vaccines.Recommendations for pneumococcal immunization outside routine childhood immunization programs in Western Europe.All-cause pneumonia hospitalizations in children <2 years old in sweden, 1998 to 2012: impact of pneumococcal conjugate vaccine introduction.Protection against Streptococcus pneumoniae lung infection after nasopharyngeal colonization requires both humoral and cellular immune responsesCost-Effectiveness Evaluation of the 10-Valent Pneumococcal Non-typeable Haemophilus influenzae Protein D Conjugate Vaccine and 13-Valent Pneumococcal Vaccine in Japanese ChildrenAssociation of pneumococcal conjugate vaccination with rates of ventilation tube insertion in Denmark: population-based register studyUsing Standardized Interpretation of Chest Radiographs to Identify Adults with Bacterial Pneumonia--Guatemala, 2007-2012.Genomics Reveals the Worldwide Distribution of Multidrug-Resistant Serotype 6E PneumococciTowards New Broader Spectrum Pneumococcal Vaccines: The Future of Pneumococcal Disease Prevention.Streptococcus pneumoniae and Haemophilus influenzae in paediatric meningitis patients at Goroka General Hospital, Papua New Guinea: serotype distribution and antimicrobial susceptibility in the pre-vaccine era.Safety and tolerability of 13-valent pneumococcal conjugate vaccine in the elderly.Impact of Pneumococcal Conjugate Universal Routine Vaccination on Pneumococcal Disease in Italian Children.Immunological Features and Clinical Benefits of Conjugate Vaccines against Bacteria.Reduction of Streptococcus pneumoniae in upper respiratory tract cultures and a decreased incidence of related acute otitis media following introduction of childhood pneumococcal conjugate vaccines in a Swedish countyAn outbreak of pneumococcal meningitis among older children (≥5 years) and adults after the implementation of an infant vaccination programme with the 13-valent pneumococcal conjugate vaccine in Ghana.Protection from the acquisition of Staphylococcus aureus nasal carriage by cross-reactive antibody to a pneumococcal dehydrogenaseEvolving pneumococcal serotypes and sequence types in relation to high antibiotic stress and conditional pneumococcal immunization.Impact of the 13-Valent Pneumococcal Conjugate Vaccine on Clinical and Hypoxemic Childhood Pneumonia over Three Years in Central Malawi: An Observational Study.Effects of PCV7 and PCV13 on invasive pneumococcal disease and carriage in Stockholm, Sweden.Epidemiology of community-acquired pneumonia and implications for vaccination of children living in developing and newly industrialized countries: A systematic literature review.Incidence of pediatric invasive pneumococcal disease in the Island of Majorca (2008-2010), an area with non-universal vaccination, and estimations of serotype & children population coverage by available conjugate vaccinesCost-effectiveness analysis of infant universal routine pneumococcal vaccination in Malaysia and Hong Kong.Age-dependent prevalence of nasopharyngeal carriage of streptococcus pneumoniae before conjugate vaccine introduction: a prediction model based on a meta-analysisImpact of the pneumococcal 10-valent vaccine on reducing hospitalization for community-acquired pneumonia in children.The impact of pneumococcal conjugate vaccine on community-acquired pneumonia hospitalizations in children with comorbidity.The impact of 7-valent pneumococcal conjugate vaccine on invasive pneumococcal disease: a literature review.Genome-based bacterial vaccines: current state and future outlook.13-valent pneumococcal conjugate vaccine: a review of its use in infants, children, and adolescents.Vaccines for children and adults with chronic lung disease: efficacy against acute exacerbations.Predicting the impact of new pneumococcal conjugate vaccines: serotype composition is not enough.Expansion of serotype coverage in the universal pediatric vaccination calendar: short-term effects on age- and serotype-dependent incidence of invasive pneumococcal clinical presentations in Madrid, Spain.
P2860
Q26782963-27D511EC-7BA2-429A-BD5C-F9E546AC2EC9Q26799527-CEC8F917-B20E-406F-BD07-F7D2D23439DAQ26824961-ACF8988E-4187-470B-9F0A-98EC62DA53EBQ27013155-65570D9A-346B-4A63-BD17-4CFA46DD86D7Q30375739-AAD3D26D-A54E-414C-AD5A-32F47CBBBE0FQ30377116-D3F33FF9-3F57-4458-A6A4-5F1EC3B2D2FAQ31136900-1D51A65D-3F7B-4D48-96F2-95E60BAEEA7BQ33706016-4FDF77F6-C884-4481-97DF-34D6192E8ED5Q33721240-C565A123-96D6-44B7-A725-0F2B5B3A8E70Q34080726-4976F438-7966-4EDA-9A74-9CD411A62724Q34402444-76016003-CC0A-48D3-A7CC-758F9529ABE8Q34473127-03A52810-9855-4DA3-95CA-60317991F622Q35154329-FCC4F6F8-D9FD-41EB-8D7C-EFE2C07C2569Q35186834-DDF1BC96-2D52-4830-8935-C34E8378E2BCQ35691633-0DD314B3-31E0-4EAB-9379-75F5BC1DF22EQ35711247-BFE4AA9A-213B-42D7-BF98-1577C2E1152FQ35757571-6221BBAC-C764-411E-BE78-8AC95FCFE0D4Q35826592-0B79055B-6FAD-469A-9540-3375E550F56DQ35828587-1EABC183-BA10-4EF4-9650-7694A64D50D8Q35886979-5B947DC4-DD14-40AA-9336-30231D9725FDQ36006193-5EE831B0-FF42-4C2C-8FCA-ECCEE49BF5A2Q36016022-AED44CC1-8324-4E76-A874-2B395516389CQ36101864-1979CC6E-5300-4FC3-9F72-C0A3A5B84BDBQ36166629-079CA5D5-6F4E-4E71-95B7-BFC148AAF2F1Q36187255-28BCE7F4-B3F3-4D0B-8056-05EF5EEE6E01Q36237724-7DDDB005-794B-447F-B1B0-1177469B5417Q36239337-6E6FBDF3-273E-4372-8D72-22275D50708DQ36762692-18C3E3F5-7D62-4ECE-9534-4B65A90187B1Q37264943-0D3202AD-3490-468A-90D5-650521900082Q37305101-C8812D1A-CD19-4C92-AB88-B33B3491AA2BQ37309195-89B91BEB-C8DD-44C5-B0F8-8F7F6E6E1DB8Q37509931-4ED790B1-98F4-456C-AEBE-4B1C71DE8044Q37524274-8C3BD388-B62B-4CF7-8FF0-A52DF443E160Q37660542-F248F06C-F660-45C5-A89F-2F14ADC9015CQ38080478-9898867E-F99B-4535-8E6F-2C73B3426348Q38099207-66F7A4AC-72F8-4AA9-8350-79F9E5144F00Q38137006-5C70F118-9B7E-4D8E-8DA4-58D3D19234D3Q38168915-C505B7EE-A244-42BE-A7D2-C4AE472939FEQ38255287-6A8CFDF7-E4FD-4BB0-9BFE-72CD4E20B385Q38425055-FC0E668B-9667-4547-86FD-4EA1D163D026
P2860
The worldwide impact of the seven-valent pneumococcal conjugate vaccine.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
The worldwide impact of the seven-valent pneumococcal conjugate vaccine.
@en
The worldwide impact of the seven-valent pneumococcal conjugate vaccine.
@nl
type
label
The worldwide impact of the seven-valent pneumococcal conjugate vaccine.
@en
The worldwide impact of the seven-valent pneumococcal conjugate vaccine.
@nl
prefLabel
The worldwide impact of the seven-valent pneumococcal conjugate vaccine.
@en
The worldwide impact of the seven-valent pneumococcal conjugate vaccine.
@nl
P2093
P1476
The worldwide impact of the seven-valent pneumococcal conjugate vaccine.
@en
P2093
Aruna Chandran
Hope L Johnson
Sean P Fitzwater
P304
P356
10.1097/INF.0B013E31824DE9F6
P577
2012-05-01T00:00:00Z